165 related articles for article (PubMed ID: 29343865)
1. Targeting murine leukemic stem cells by antibody functionalized mesoporous silica nanoparticles.
Mandal T; Beck M; Kirsten N; Lindén M; Buske C
Sci Rep; 2018 Jan; 8(1):989. PubMed ID: 29343865
[TBL] [Abstract][Full Text] [Related]
2. Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy.
Guo J; Russell EG; Darcy R; Cotter TG; McKenna SL; Cahill MR; O'Driscoll CM
Mol Pharm; 2017 Mar; 14(3):940-952. PubMed ID: 28146632
[TBL] [Abstract][Full Text] [Related]
3. The effect of cantharidins on leukemic stem cells.
Dorn DC; Kou CA; Png KJ; Moore MA
Int J Cancer; 2009 May; 124(9):2186-99. PubMed ID: 19123473
[TBL] [Abstract][Full Text] [Related]
4. Characterization of high-affinity peptides and their feasibility for use in nanotherapeutics targeting leukemia stem cells.
Zhang H; Luo J; Li Y; Henderson PT; Wang Y; Wachsmann-Hogiu S; Zhao W; Lam KS; Pan CX
Nanomedicine; 2012 Oct; 8(7):1116-24. PubMed ID: 22197725
[TBL] [Abstract][Full Text] [Related]
5. Targeting of CD44 eradicates human acute myeloid leukemic stem cells.
Jin L; Hope KJ; Zhai Q; Smadja-Joffe F; Dick JE
Nat Med; 2006 Oct; 12(10):1167-74. PubMed ID: 16998484
[TBL] [Abstract][Full Text] [Related]
6. CGRP Signaling via CALCRL Increases Chemotherapy Resistance and Stem Cell Properties in Acute Myeloid Leukemia.
Gluexam T; Grandits AM; Schlerka A; Nguyen CH; Etzler J; Finkes T; Fuchs M; Scheid C; Heller G; Hackl H; Harrer N; Sill H; Koller E; Stoiber D; Sommergruber W; Wieser R
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31756985
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells.
Jin L; Lee EM; Ramshaw HS; Busfield SJ; Peoppl AG; Wilkinson L; Guthridge MA; Thomas D; Barry EF; Boyd A; Gearing DP; Vairo G; Lopez AF; Dick JE; Lock RB
Cell Stem Cell; 2009 Jul; 5(1):31-42. PubMed ID: 19570512
[TBL] [Abstract][Full Text] [Related]
8. Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells.
Pelosi E; Castelli G; Testa U
Blood Cells Mol Dis; 2015 Dec; 55(4):336-46. PubMed ID: 26460257
[TBL] [Abstract][Full Text] [Related]
9. Construction of a target MSNs drugcarrier loaded with siRNA
Zhang Y; Cai R; Li H; Duan Y; Zhang Y; Jing W; Lv S; Chu X; Cao Z; Yang L; Ming L
Drug Deliv Transl Res; 2022 Oct; 12(10):2463-2473. PubMed ID: 35113326
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
[TBL] [Abstract][Full Text] [Related]
11. Daunorubicin-containing CLL1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia.
Lin TY; Zhu Y; Li Y; Zhang H; Ma AH; Long Q; Keck J; Lam KS; Pan CX; Jonas BA
Nanomedicine; 2019 Aug; 20():102004. PubMed ID: 31055076
[TBL] [Abstract][Full Text] [Related]
12. TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells.
Kikushige Y; Miyamoto T
Int J Hematol; 2013 Dec; 98(6):627-33. PubMed ID: 24046178
[TBL] [Abstract][Full Text] [Related]
13. TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia.
Kikushige Y; Akashi K
Ann N Y Acad Sci; 2012 Aug; 1266():118-23. PubMed ID: 22901263
[TBL] [Abstract][Full Text] [Related]
14. Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia.
Dorrance AM; Neviani P; Ferenchak GJ; Huang X; Nicolet D; Maharry KS; Ozer HG; Hoellarbauer P; Khalife J; Hill EB; Yadav M; Bolon BN; Lee RJ; Lee LJ; Croce CM; Garzon R; Caligiuri MA; Bloomfield CD; Marcucci G
Leukemia; 2015 Nov; 29(11):2143-53. PubMed ID: 26055302
[TBL] [Abstract][Full Text] [Related]
15. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.
Kikushige Y; Shima T; Takayanagi S; Urata S; Miyamoto T; Iwasaki H; Takenaka K; Teshima T; Tanaka T; Inagaki Y; Akashi K
Cell Stem Cell; 2010 Dec; 7(6):708-17. PubMed ID: 21112565
[TBL] [Abstract][Full Text] [Related]
16. Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia.
Laing AA; Harrison CJ; Gibson BES; Keeshan K
Exp Hematol; 2017 Oct; 54():40-50. PubMed ID: 28668350
[TBL] [Abstract][Full Text] [Related]
17. A surface-grafted ligand functionalization strategy for coordinate binding of doxorubicin at surface of PEGylated mesoporous silica nanoparticles: Toward pH-responsive drug delivery.
Zhang Q; Zhao H; Li D; Liu L; Du S
Colloids Surf B Biointerfaces; 2017 Jan; 149():138-145. PubMed ID: 27750088
[TBL] [Abstract][Full Text] [Related]
18. Understanding of leukemic stem cells and their clinical implications.
Wang X; Huang S; Chen JL
Mol Cancer; 2017 Jan; 16(1):2. PubMed ID: 28137304
[TBL] [Abstract][Full Text] [Related]
19. [New approaches to target leukemia stem cells].
Takenaka K; Akashi K
Nihon Rinsho; 2014 Jun; 72(6):1018-25. PubMed ID: 25016798
[TBL] [Abstract][Full Text] [Related]
20. Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors.
Venton G; Pérez-Alea M; Baier C; Fournet G; Quash G; Labiad Y; Martin G; Sanderson F; Poullin P; Suchon P; Farnault L; Nguyen C; Brunet C; Ceylan I; Costello RT
Blood Cancer J; 2016 Sep; 6(9):e469. PubMed ID: 27611922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
